

## Prevalence of *Shigella* Species and Their Antimicrobial Resistance Patterns at Amirkola Children's Hospital, North of Iran

Rahim Barari Savadkoohi\*<sup>1</sup>, MD; Mousa Ahmadpour-Kacho<sup>2</sup>, MD

1. Pediatric Infectious Disease Specialist, Babol University of Medical Sciences. Babol, IR Iran
2. Pediatrician and Neonatologist, Babol University of Medical Sciences. Babol, IR Iran

Received: 1/12/06; Revised: 18/01/07; Accepted: 6/03/07

### Abstract

**Objective:** In the few cases of acute childhood diarrhea that require antimicrobial therapy, the correct choice of the drug depends on detailed previous knowledge of local strains and pattern of antimicrobial resistance. Shigellosis is one of the most important examples in this group of intestinal infections. In order to establish such parameters in our city this study was carried out to determine the prevalence and pattern of antimicrobial resistance of *Shigella* species among patients with acute diarrhea admitted to the Amirkola children's hospital, North of Iran.

**Material & Methods:** The study included all patients with acute diarrhea, 6 months to 12 years of age, who were admitted to the Amirkola children's hospital during March 2001 to March 2004. Incidence, phenotypic characteristics and antimicrobial resistance patterns of *Shigella* strains, isolated from hospitalized children with acute diarrhea, were studied

**Findings:** We received 260 positive cultures for *Shigella* out of 1850 stool samples during 3 years (14.05%). *Shigella* specimens presented a high resistance rate to trimethoprim-sulfamethoxazole (73.84%) and ampicillin (73.84%), and low resistance rate to Ciproflaxacin (2.69%) and cefotaxim (2.69%). *S. flexneri* (70%) was most frequently isolated, followed by *S. Sonnei* (30 %). No cases of *S. boydii* and *S. dysenteriae* were found.

**Conclusion:** Our results provide data on antimicrobial resistance to choose a proper antibiotic for Shigellosis in our community. According to our findings cefotaxime for pediatric patients and quinolone derivatives for adult patients are the proper drug choices. Systematic monitoring is needed to identify changes in prevalence and antimicrobial resistance pattern.

**Key Words:** *Shigella*, Prevalence, Antimicrobial resistance, Children, Diarrhea

\* Correspondence author.

Address: No 19, Shafa St, Amirkola Children Hospital, Amirkola, Babol, Mazandaran, 47317- 4 1151, Iran

E-mail: sawadkohl330@yahoo.com

## Introduction

Knowledge of local patterns of resistance is essential to optimize guidelines for empirical antimicrobial treatment. Awareness of susceptibility patterns in other parts of the world may be important for determining empirical antimicrobial therapy for diarrhea patients<sup>[1]</sup>.

*Shigella* is one of the most important causes of gastroenteritis and death of 3-5 millions of children under the age of 5 years in developing countries<sup>[2,3,4]</sup>. Ingestion of even 100 microorganisms leads after 4-7 days to an acute diarrhea. Because of delay in humoral responses, complication and mortality rate due to shigellosis in children is higher than in other age groups<sup>[5,6]</sup>. Early diagnosis and drug therapy in children is imperative because of high tendency for occurrence of complications<sup>[2]</sup>. According to WHO report, antimicrobial resistance pattern for *shigella* varies in different parts of the world and with the time<sup>[6]</sup>. This microorganism may also be able to show antibacterial resistance during the course of the drug therapy<sup>[7]</sup>.

The predominant *shigella* strains isolated in Karaj, Iran, was *shigella flexeneri* and the least common antimicrobial resistance belonged to Nalidixic acid<sup>[8]</sup>. In Kashan, Iran, the most sensitive antibacterial agent for *shigella* was ciprofloxacin<sup>[9]</sup>. *Shigella* strains isolated from stool samples of children in Mofid hospital in Tehran were resistant to co-trimoxazol (98.5%) and ampicillin (84.6%). Only 10% were resistant to Nalidixic acid<sup>[10]</sup>.

The most prevalent *shigella* strain in a Turkish study was *shigella sonnei*. Seventy nine percent of isolated strains were resistant to streptomycin, 56% to tetracyclin and 55.7% to trimethoprim-sulfamethaxazol. None of the isolates was resistant to ciprofloxacin, nalidixic acid, cephalosporin or ceftriaxon<sup>[11]</sup>.

Of 4688 stool samples cultured in Karachi, Pakistan, 193 (4.1%) were positive for *shigella* species. *Shigella flexeneri* was the predominant serogroup followed by *shigella sonnei*. All isolates were susceptible to ofloxacin and ceftriaxon. High rates of resistance were observed for co-trimoxazol and ampicillin<sup>[12]</sup>.

## Material & Methods

This is a cross-sectional study, carried out on diarrhea patients admitted to Amirkola children's hospital affiliated to Babol University of Medical Sciences, North of Iran, from 2001-2004.

The study included all children older than six months with an acute diarrhea who were admitted to the hospital. Children with a history of chronic diarrhea, immunodeficiency, malnutrition and chronic illness were excluded. Fresh stool was taken from all patients, and cultured on SS agar media (Kooshanfar Azar Giti KFG. Company, Iran).

Antibiotic sensitivity of isolated strains was identified with disk diffusion method using 15 different antibiotic disks. Capability to growth in the presence of bactericidal level of an antibiotic in media was considered being resistant. Resistance or sensitivity is defined according to the size of the inhibition made around the disks and it correlates with standard minimal inhibitory concentration (MIC) which is the lowest concentration that visibly inhibits bacterial growth to permit extrapolation from this simple test to the more complicated agar or broth dilution MIC test. For recognition of *Shigella* species one drop of antisera of *Shigella* added to bacterial colony, which make agglutination after 2 minutes. We estimated a sample size of 1800 patients, if we consider  $d=0.02$ ,  $p=0.1$  and  $\alpha=0.05$ .

Demographic data like age, sex, and place of residence (rural or urban) and the season of year were collected by a questionnaire. These data are analyzed by SPSS-10 and the results expressed as relative frequencies.

## Findings

From March 21, 2001 to March 21, 2004, 1850 pediatric patients (6 month - 12 years) were admitted because of diarrhea with moderate to severe dehydration. *Shigella* was grown on 260 out of 1850 stool cultures (14.5%).

One-hundred forty six patients (56.15%) were male and 114 (43.85%) female. One-

hundred eight (41.54%) came from rural area and 152 were urban. Most of the cases of shigellosis (57%) were admitted to the hospital in summer. Only 35 (13.46%) of the patients were infants.

The most common affected age group was 1-5 years and the least common affected age group was that of infants aged 2-11 months. *Shigella* species typing revealed 70% *S. flexeneri* and 30% *S. Sonnei*. Antimicrobial resistance pattern to the commonly used antibiotics for shigellosis is showed on table 1.

## Discussion

The prevalence of Shigellosis among diarrhea patients in our hospital was 14.05%, which is higher than the rate reported for Karachi, Pakistan<sup>[12]</sup>. In another study the prevalence of shigellosis was increased from 5.8% to 16.8% for a period of 10 years in Karaj and Tehran, Iran<sup>[13]</sup>. Some studies from other parts of the world report similar findings. For example in Malaysia the prevalence of shigellosis was

increased from 8.5% in 1992 to 13% in 2003<sup>[14]</sup>.

The predominant species of *Shigella* in our study was *S. flexeneri*, followed by *S. sonnei*, which is the same predominant species in Pakistan<sup>[12]</sup>. The predominant species in other parts of Iran differ from our study for example in Shiraz the predominant species was *S. Sonnei* followed by *S. flexeneri*<sup>[15]</sup>; in Tehran the predominant species reported was *S. Boiedi* followed by *S. Sonnei*<sup>[16]</sup>. The predominant species in most parts of the world is *S. Sonnei* followed by *S. flexeneri*<sup>[17,18]</sup>; in Nepal it was reported to be *S. Dysentriae* followed by *S. flexeneri*<sup>[19]</sup>.

Most of our patients came from rural area and the prevalence of antibacterial resistance in these patients was higher than the in the urban areas. In rural patients, recurrent disease may be related to low hygienic behavior, cultural and economical reason and also the unavailability of clean water.

In our study, like in other studies, the seasonal tendency of shigellosis was summer<sup>[17,19]</sup>. The prevalence of antimicrobial

**Table 1:** Bacterial resistance pattern of *Shigella* for commonly used antibiotics- Amirkola children's hospital

<i>Antibiotics</i>	<i>Bacterial resistance (%)</i>
<b>Co-trimoxazol</b>	192 (73.8)
<b>Tetracycline</b>	192 (73.8)
<b>Ampicillin</b>	78 (30.0)
<b>Kanamycin</b>	54 (20.8)
<b>Ceftriaxone</b>	47 (18.1)
<b>Cefazoline</b>	38 (14.6)
<b>Nalidixic acid</b>	32 (12.3)
<b>Chloramphenicol</b>	32 (12.3)
<b>Cephalotin</b>	23 (8.8)
<b>Toberomycine</b>	23 (8.8)
<b>Ceftizoxime</b>	7 (2.7)
<b>Ceftazidime</b>	7 (2.7)
<b>Gentamycin</b>	7 (2.7)
<b>Ciproflaxacine</b>	7 (2.7)
<b>Cefotaxime</b>	7 (2.7)

resistance according to the season of occurrence for summer; autumn and spring were 87%, 73% and 22% respectively. The increase in the prevalence of disease and also the antimicrobial resistance in summer may be due to increase in the entrance of travelers and the emergence of new resistant species in our area<sup>[19,20]</sup>. The susceptible age group in our study, like in other studies, was age 1-5 years; 6-11 month-old infants were the least common affected age group. This may be due to the breast-feeding which plays the crucial role for protection against gastrointestinal infections<sup>[21,22]</sup>.

The pattern of antimicrobial resistance in our study was mostly a multidrug resistance. This is similar to other studies<sup>[7,23]</sup>. The most common antibacterial resistance was observed for trimetoprim-sulfamethaxazol, tetracycline and ampicillin. Similar patterns of resistance were reported from Chile, Pakistan, Turkey, India and Nepal<sup>[11,18,19,24]</sup>.

Some of these studies used tube dilution method for determining bacterial resistance whereas we have used disk diffusion method. Ceftrizoxime, ceftazidime, gentamicin, ciprofloxacin and cefotaxime were the least common antimicrobial resistant agents. In a recent study Alici and colleagues did not report any resistance to ciprofloxacin for *Shigella*<sup>[19]</sup>. Fulla and colleagues also reported no resistance to ciprofloxacin, Cefotaxime and Nalidixic acid<sup>[24]</sup>. This drug was recommended as a drug of choice for treatment of shigellosis in France<sup>[5]</sup>.

## Conclusion

According to our finding Cefotaxim for pediatric patients and quinolones derivatives for adult patient are the proper choices.

## Acknowledgment

We thank all nurses of the Amirkola children's hospital and especially our colleagues in the clinical laboratory.

## References

1. Jumaa PA, Neringer R. A survey of antimicrobial resistance in a tertiary referral hospital in the United Arab Emirates. *Chemother*. 2005; 17(4):376-9.
2. Raqib R, Sarker P, Bergman P, et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. *Proc Natl Acad Sci USA*. 2006; 103(24): 9178-83.
3. Sur D, Ramamurthy T, Deen J, et al. Shigellosis: challenges and management issues. *Indian J Med Res*. 2004;120(5):454-62.
4. Ashkenazi S. Shigella infections in children: New insights. *Semin Pediatr Infect Dis*. 2004; 15(4): 246-52.
5. Agence Francaise de Securite Sanitaire des Produits de Sante. Antibiotic treatment of *shigella sonnei* gastroenteritis, *Presse Med*. 2004;33(21):1538-45.
6. WHO: Shigella. Available at: [www.who.int/vaccineresearch/diseases/shigella/en](http://www.who.int/vaccineresearch/diseases/shigella/en). Access date: Jan, 4 2007.
7. Ozmert EN, Gokturk B, Yurdakok K, et al. Shigella antibiotic resistance in central Turkey: Comparison of the years 1987-1994 and 1995-2002. *J Pediatr Gastroenterol Nurt*. 2005; 40(3):359-62.
8. Zali MR, Ardalan KM, Rezaei-Homami M, et al. Incidence, seasonal trend and antimicrobial resistance of Shigella in Karaj, Tehran province, Iran. *Iran J Infect Dis Trop Med*. 1381; 19(7): 10-11.
9. Afzali H, Taghavi A, Rasa H. Evaluation of antibiotic sensitivity of shigella, salmonella and vibrio cholera in patients with acute diarrhea referred to reference laboratory of Kashan University of Medical Sciences from 2000-2001. *Feyz*. 2001; 19(5): 47-58.
10. Ayazi P. Prevalence of clinical symptoms and antimicrobial sensitivity of shigella in children. *J Qazvin Univ Med Sciences*. 2001;16(4):46-50. (Persian)
11. Ayser AD, Guriz H. Drug resistance of shigella strains isolated in Ankara, Turkey 1993-1996. *Scand J Infec Dis*. 1998; 30(4): 351-3.
12. Zafar A, Sabir N, Bhutta ZA. Frequency of isolation of shigella serogroups/scrotypes and their antimicrobial susceptibility pattern in children from slum area in Karachi. *J Pak Med Assoc*. 2005;55(5):184-8.
13. Moez-ardalan A, Zali MR, Soltan-Dallal MM, et al. Prevalence and pattern of

- microbacterial resistance of shigella species patients with acute diarrhea in Karaj & Tehran, Iran. *J Health Population Nutr.* 2003;21(2):96-102.
14. Lee WS, Putha-Sheary SD. Species distribution and antibiotic resistance of shigella isolated in an urban community in Malaysia. *Med J Malaysia.* 2003;58(2): 262-7.
  15. Farshad S, Sheikha R, Japoni A, et al. Characterization of shigella strains in Iran by plasmid profile analysis and PCR amplification of ipagenes. *J Clin Microbiol.* 2006;44(8):2879-83.
  16. Katouli M, Pachenary A, Jaafari A, et al. The role of shigella Spp. in childhood diarrhoea in Iran and their antibiotic resistance. *Scand J infect Dis.* 1989;21(4): 415-9.
  17. Ekdaha K, Andersson Y. The epidemiology of travel-associated shigellosis - regional risks, seasonality and serogroups. *J Infect.* 2005;51(3):222-9.
  18. Pazhani GP, Rumamurthy T, Mitra U, et al. Species diversity and antimicrobial resistance of shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. 2005; 133(6):1089-95.
  19. Alici O, Acikgoz ZC, Gamberzade S, et al. Antibiotic resistance rates of shigella species isolated from stool cultures in the years 1999-2003. *Mikrobiyol Bul.* 2006; 40(1-2):9-14.
  20. Gascon J. Epidemiology, etiology and pathophysiology of travelers' diarrhea. *Digestion.* 2006; 73(suppl 1): 102-8.
  21. Wang XY, Dul, von Seidlein L. Occurrence of shigellosis in the young and elderly in rural china: results of a 12 month population based surveillance study. *Am J Trop Med Hyg.* 2005; 73(2): 416-22.
  22. Willer EM, Lima Rade L, Giugliano LG. In vitro adhesion and invasion inhibition of *Shigella dysenteriae*, *Shigella flexneri* and *Shigella sonnei* clinical strains by human milk proteins. *BMC Microbiol.* 2004;4:18. (e-Journal)
  23. Badalian K, Tavakoli H. Transfer of drug resistance factor in *Shigella sonnei* isolated in Iran. *Pahlavi Med J.* 1976;7(1):71-91.
  24. Fulla N, Prado V, Duran C, et al. Surveillance for antimicrobial resistance profiles among shigella species isolated from a semirural community. 2005;72(6): 85-4.

Archive of